Analyst Price Target is $64.29
▲ +179.26% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $64.29, with a high forecast of $80.00 and a low forecast of $40.00. The average price target represents a 179.26% upside from the last price of $23.02.
Current Consensus is
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Jasper Therapeutics. This Buy consensus rating has held steady for over two years.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Read More
